Fine lines & wrinkles
The peptide is used in skincare to improve visible signs of photoageing.
Explore the research →COSMETIC PEPTIDE & COLLAGEN SIGNALLING
Palmitoyl Pentapeptide-4
A topical cosmetic peptide best known for collagen-related signalling and research into fine lines, wrinkles and photoaged skin.
Fine linesCollagenPhotoageing
Human topical evidence existsA randomized split-face study found a palmitoyl pentapeptide formulation improved fine lines and wrinkles compared with its vehicle over 12 weeks.
FOLLOW THE FULL PICTUREFrom interest to evidence, quality and the numbers.
Why are people interested in Palmitoyl Pentapeptide-4?
Palmitoyl Pentapeptide-4 is one of the better-known cosmetic peptides because its purpose is straightforward: support the skin's collagen-related repair signalling and improve the look of fine lines. Unlike many injectable research peptides, its story is primarily topical and cosmetic.
Collagen signalling
Pal-KTTKS was designed from a collagen-related signalling sequence and modified for topical use.
Explore the research →Skin texture
Improved matrix support may contribute to smoother-looking skin over time.
Explore the research →Topical use
Its evidence base concerns application to skin rather than systemic administration.
Explore the research →THE SCIENCE BIT
A collagen-inspired message for skin cells.
Palmitoyl pentapeptide-4 combines the five-amino-acid KTTKS sequence with a fatty-acid tail. The sequence comes from a collagen-related fragment and is studied for signalling to dermal fibroblasts.
Cell studies examine extracellular-matrix production, while cosmetic trials test skin appearance. The lipid tail influences the molecule's properties; it does not guarantee delivery to every layer of skin.
See the studies & trials →- KTTKS
- Collagen-related sequence
- Palmitoyl tail
- Changes physical properties
- Fibroblasts
- Matrix-production research
How this connects to the research
Topical cosmetic evidence and laboratory signalling research.
Read a primary source ↗FROM MOLECULE TO TISSUE
Where Palmitoyl Pentapeptide-4 connects with the body
These are the tissues and biological systems behind the interest in Palmitoyl Pentapeptide-4.
- Dermis
- Fibroblasts and collagen.
- Skin matrix
- Structural-protein research.
- Skin surface
- Cosmetic appearance outcomes.
The research behind the interest
Fine lines & wrinkles
The peptide is used in skincare to improve visible signs of photoageing.
A 12-week randomized split-face study found significant wrinkle and fine-line improvement versus the control moisturiser.
Human cosmetic evidenceExplore the studies →Collagen signalling
Pal-KTTKS was designed from a collagen-related signalling sequence and modified for topical use.
Laboratory work supports extracellular-matrix signalling as the rationale.
Mechanistic evidenceExplore the studies →Skin texture
Improved matrix support may contribute to smoother-looking skin over time.
Clinical evidence is more developed for wrinkles than for broad claims about skin regeneration.
Developing human evidenceExplore the studies →Topical use
Its evidence base concerns application to skin rather than systemic administration.
That makes it a very different proposition from injectable research compounds on the site.
Established route contextExplore the studies →Studies & trials
Studies & trials
Original publication · PubMed · trial registry where availableTopical palmitoyl pentapeptide in photoaged facial skin ↗
93 women aged 35–55
Topical12 weeks
The pal-KTTKS moisturiser significantly improved wrinkles and fine lines compared with the vehicle control.
The formulation was well tolerated.
Evidence snapshot
Evidence snapshot
Separate dimensions, not one overall score◎
Human evidenceStrong
4/5 evidence depth
Controlled topical human studies are available.
✓
Clinical efficacyDeveloping
3/5 evidence depth
Visible wrinkle improvement has been demonstrated for specific formulations.
◇
Safety evidenceStrong
4/5 evidence depth
Topical tolerability is reasonably characterised in cosmetic studies.
⌁
Preclinical evidenceStrong
4/5 evidence depth
Mechanistic skin and matrix research supports the rationale.
HOW TO READ THESE SCORESStrong preclinical evidence · strong human evidence
These are editorial evidence-depth ratings on a 1–5 scale, not a statistical result or a single scientific formula. They summarise how much relevant evidence is present in each separate category and how mature that evidence is.
Human evidenceHow much direct research in people is available and how developed it is.
Clinical efficacyWhether human studies demonstrate meaningful outcomes for the claims being discussed.
Safety evidenceHow much human safety, tolerability and longer-term follow-up information is available.
Preclinical evidenceThe depth of laboratory and animal research supporting biological plausibility.
HOW THE EVIDENCE IS ORGANISED
Palmitoyl Pentapeptide-4 research profile
Research themes are shown separately from the strength of the human evidence so biological interest is not confused with proven clinical benefit.
RESEARCH AREA 01Fine lines
RESEARCH AREA 02Collagen
RESEARCH AREA 03Photoageing
RESEARCH AREA 04Skin texture
Mechanistic and preclinical findings are context for further research; they are not treated as equivalent to demonstrated human outcomes.
From promising signals to human evidencePreclinical research can reveal promising biological signals. Human studies show how far those signals have translated into real-world outcomes.
What people are exploring
COMMUNITY · USE CASES & EXPERIENCE
What people want to change with Palmitoyl Pentapeptide-4
Interest is mainly cosmetic: fine lines, skin texture and collagen-support claims.
Explore the everyday goalsConceptual scientific illustration
THE PRACTICAL ATTRACTION
The goals behind the interest
What the desired change means in daily life, and what makes an experience useful to understand.
Softening fine lines
Skincare interest centres on subtler lines and a smoother-looking surface. The practical question is whether a finished topical formulation produces a visible improvement over consistent use.
- What makes a report informative
- Comparable photographs of the same area and lighting.
- What can muddy the picture
- Moisturising ingredients can improve line appearance independently of the peptide.
Texture and firmer-looking skin
People hope for skin that looks more even and resilient. Collagen-related signalling explains the interest, while cosmetic appearance does not directly measure new collagen in the skin.
- What makes a report informative
- Texture and firmness appearance with the full skincare routine.
- What can muddy the picture
- Retinoids, exfoliation, sun protection and formulation affect the result.
A routine that supports longer-term skin quality
Interest often involves adding a peptide serum or cream to an existing routine. The relevant experience is tolerability and gradual appearance change, not assuming every product with the ingredient performs alike.
- What makes a report informative
- The complete formula and consistent appearance over time.
- What can muddy the picture
- Ingredient studies cannot guarantee the performance of every finished product.
PUT THE EXPERIENCE IN CONTEXT
How the goals compare with the research
Open an area to distinguish human findings from laboratory explanations.
Fine lines & wrinkles
A 12-week randomized split-face study found significant wrinkle and fine-line improvement versus the control moisturiser.
Evidence context: Human cosmetic evidence
Collagen signalling
Laboratory work supports extracellular-matrix signalling as the rationale.
Evidence context: Mechanistic evidence
Skin texture
Clinical evidence is more developed for wrinkles than for broad claims about skin regeneration.
Evidence context: Developing human evidence
Topical use
That makes it a very different proposition from injectable research compounds on the site.
Evidence context: Established route context
The biological rationale
Palmitoyl pentapeptide-4 combines the five-amino-acid KTTKS sequence with a fatty-acid tail. The sequence comes from a collagen-related fragment and is studied for signalling to dermal fibroblasts.
Cell studies examine extracellular-matrix production, while cosmetic trials test skin appearance. The lipid tail influences the molecule's properties; it does not guarantee delivery to every layer of skin.
Research sources and further reading
Dose & duration
DOSE & DURATION
Research protocols · community patterns · calculator toolsSee the numbers in their proper context
See the amount, how often it was used and how long each study ran. Published human research and community descriptions each carry their own source label, so you can see where the numbers came from.
Source matters. The figures below show authorised, human-research or community-described protocols in their original context — not a personalised recommendation.
Evidence relates to formulated topical skincare products rather than injectable dosing.
No structured human dosing protocol has been added for this compound. That should not be interpreted as evidence for a community dosing schedule.
CALCULATOR TOOLS
Work with the numbers
Convert amounts, concentration, liquid volume and vial requirements. These tools do the arithmetic; they do not select a dose.
NEED HELP READING THE NUMBERS?Source labels, routes and dose termsOpen guide +
HOW WE LABEL NUMBERSKnow where a dose came from before you compare it.
Authorised labelHuman trialCommunity-describedBEFORE THE NUMBERS: CHECK THE PRODUCT
Understand peptide testing →A dose only means something if the vial contains what the label says.
Purity, identity, quantity, sterility and endotoxin testing answer different questions. Learn how to read a COA and why a high purity percentage is not the same as confirming the amount in the vial.
READ THIS PAGE IN THREE STEPS
Understand the study before the number
A dose only makes sense alongside the population, route, frequency and duration. Start with where the number came from, then look at how it was delivered and how long the study actually ran.
1Source
Was it an authorised label, a human trial or a community-described pattern?
2Route & frequency
How was it given, and how often? The same number by a different route may not mean the same exposure.
3Duration
Was this one dose, a short trial or long-term treatment? A study window is not automatically a recommended cycle.
ROUTES EXPLAINED
Plain-English guideWhat do the injection types mean?
Route means how a compound was delivered. It affects absorption and can completely change how a study should be interpreted.
SubQ / SCSubcutaneous
An injection into the fatty layer just under the skin.
Common in peptide and metabolic-drug studies. It usually aims for systemic absorption rather than treating only the spot injected.IMIntramuscular
An injection into muscle tissue.
Muscle can absorb a medicine differently from fat. An IM amount should not be assumed to be equivalent to a SubQ amount.IVIntravenous
Delivered directly into a vein.
This gives immediate bloodstream exposure and is commonly used in supervised research or clinical settings. It is not interchangeable with a home injection route.INIntranasal
Delivered through the nose rather than by injection.
The amount delivered depends on formulation and device. A spray count alone does not tell you the dose unless concentration and spray volume are known.Other routes you may see:Oral = swallowed.Topical = applied to skin or another surface.Implant = a formulation placed under the skin by a trained professional.
CALENDAR SETUP
Topical product reminder guide
Human cosmetic study · formulation-specificThe 12-week skin study used a moisturiser containing 3 ppm pal-KTTKS. That concentration is not a milligram amount per application or an injection dose. Set application reminders from your actual product directions; no daily frequency is inferred from the study abstract.
Form and route: Topical pal-KTTKS moisturiser
The planner keeps amounts and repeat patterns blank for this compound. Use its formulation guide to record an independently specified schedule.
PLAIN-ENGLISH GLOSSARYWhat do the dose terms mean?Open glossary +
mgmilligram
One thousand micrograms (mcg).
mcg / μgmicrogram
One thousandth of a milligram.
mcg/kgweight-based dose
The amount is calculated for each kilogram of body weight.
IUinternational unit
A measure of biological activity used for some medicines; it cannot be converted to mg without compound-specific information.
Routehow it was given
For example SubQ, IM, IV, intranasal, oral or topical.
Frequencyhow often
For example once daily, twice weekly or every seven days.
Titrationplanned step-up or step-down
A protocol changes the amount over time rather than using one fixed amount throughout.
Half-lifehow quickly levels fall
The time taken for the amount of a compound in the body to reduce by roughly half. It can influence study timing but does not by itself define a schedule.
Cyclea defined period of use
Usually means an on-period followed by a stop or review. Many community 'cycles' have not been clinically validated.
Maintenancea continuing phase
A longer-term amount or interval used after an initial phase when a study or authorised treatment actually defines one.
Reconstitutionturning powder into solution
Adding a specified liquid to a freeze-dried vial so a concentration can be calculated.
U-100 unitssyringe volume markings
100 units equals 1 mL on a U-100 insulin syringe. The markings show volume, not peptide mass.
Safety context
SAFETY & UNCERTAINTY
Formulation matters
What the current evidence saysCosmetic tolerability depends on the complete product, concentration and other ingredients. Evidence for a finished topical formula cannot automatically be transferred to every product containing the peptide.
01 · OBSERVEDPublished safety findings
The summary above reflects the human or preclinical evidence currently represented on this profile.
02 · UNCERTAINGaps still matter
Limited follow-up, small studies or absent controlled trials can leave uncommon and longer-term risks unresolved.
03 · CONTEXTProduct and regulatory status
Route, product identity, quality and regulatory status can materially change the safety context; see the linked status sources below.
Sources & current status
READ FURTHER
Sources & current status
Follow the professional sources used across this profile, then see how the compound is currently described in regulatory and research terms.
KEY RESEARCH RECORD
4 sourcesSources used on this profile
CURRENT STATUS
How to interpret its position today
No UK-authorised medicine identified for this use
Palmitoyl Pentapeptide-4 is presented here for research context. Availability online does not establish medicine quality, safety or efficacy.
MHRA products database ↗No FDA-approved therapeutic product identified for this use
Published research and commercial availability are separate from regulatory approval.
Drugs@FDA ↗Profile reviewed against its linked source record on 20 September 2026. See how evidence is assessed.